Literature DB >> 16387640

The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells.

Eva Eljaschewitsch1, Anke Witting, Christian Mawrin, Thomas Lee, Peter M Schmidt, Susanne Wolf, Heide Hoertnagl, Cedric S Raine, Regine Schneider-Stock, Robert Nitsch, Oliver Ullrich.   

Abstract

Endocannabinoids are released after brain injury and believed to attenuate neuronal damage by binding to CB(1) receptors and protecting against excitotoxicity. Such excitotoxic brain lesions initially result in primary destruction of brain parenchyma, which attracts macrophages and microglia. These inflammatory cells release toxic cytokines and free radicals, resulting in secondary neuronal damage. In this study, we show that the endocannabinoid system is highly activated during CNS inflammation and that the endocannabinoid anandamide (AEA) protects neurons from inflammatory damage by CB(1/2) receptor-mediated rapid induction of mitogen-activated protein kinase phosphatase-1 (MKP-1) in microglial cells associated with histone H3 phoshorylation of the mkp-1 gene sequence. As a result, AEA-induced rapid MKP-1 expression switches off MAPK signal transduction in microglial cells activated by stimulation of pattern recognition receptors. The release of AEA in injured CNS tissue might therefore represent a new mechanism of neuro-immune communication during CNS injury, which controls and limits immune response after primary CNS damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16387640     DOI: 10.1016/j.neuron.2005.11.027

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  150 in total

1.  Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1.

Authors:  Cheryl Isleib Blaukovitch; Raymond Pugh; Albert C Gilotti; Daniela Kanyi; Linda J Lowe-Krentz
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

2.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

5.  Minocycline Attenuates Neonatal Germinal-Matrix-Hemorrhage-Induced Neuroinflammation and Brain Edema by Activating Cannabinoid Receptor 2.

Authors:  Jun Tang; Qianwei Chen; Jing Guo; Liming Yang; Yihao Tao; Lin Li; Hongping Miao; Hua Feng; Zhi Chen; Gang Zhu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

6.  Activation of Cannabinoid Type Two Receptors (CB2) Diminish Inflammatory Responses in Macrophages and Brain Endothelium.

Authors:  Yuri Persidsky; Shongshan Fan; Holly Dykstra; Nancy L Reichenbach; Slava Rom; Servio H Ramirez
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-11       Impact factor: 4.147

7.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

8.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

Review 9.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

10.  Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons.

Authors:  Louise M Collins; Gerard W O'Keeffe; Caitriona M Long-Smith; Sean L Wyatt; Aideen M Sullivan; André Toulouse; Yvonne M Nolan
Journal:  Neuromolecular Med       Date:  2013-04-13       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.